{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:08Z","timestamp":1791179168748,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.beha.2012.04.004","type":"journal-article","created":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T09:28:55Z","timestamp":1336555735000},"page":"201-210","source":"Crossref","is-referenced-by-count":15,"title":["Radioimmunotherapy in mantle cell lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Alan P.","family":"Skarbnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beha.2012.04.004_bib1","first-page":"115","article-title":"Mantle-cell lymphoma","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.beha.2012.04.004_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a059161","article-title":"In situ hybridization detection of cyclin D1 mRNA in centrocytic\/mantle cell lymphoma","volume":"6","author":"Williams","year":"1995","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.004_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2012.04.004_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/fon.10.189","article-title":"Should there be a standard therapy for mantle cell lymphoma?","volume":"7","author":"Smith","year":"2011","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.beha.2012.04.004_bib5","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2012.04.004_bib6","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2012.04.004_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-hypercvad alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2012.04.004_bib8","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic lymphoma group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.004_bib9","first-page":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2012.04.004_bib10","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2012.04.004_bib11","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma","volume":"48","author":"Rodriguez","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2012.04.004_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2012.04.004_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.8030","article-title":"phase I\/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed\/refractory mantel cell lymphoma (MCL) with early evidence of efficacy","author":"Wang","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2012.04.004_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.004_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"issue":"15s","key":"10.1016\/j.beha.2012.04.004_bib16","article-title":"Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL)","volume":"27","author":"Paoluzzi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2012.04.004_bib17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med"},{"issue":"8400","key":"10.1016\/j.beha.2012.04.004_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(84)92907-6","article-title":"Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma","volume":"2","author":"Nadler","year":"1984","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2012.04.004_bib19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.4049\/jimmunol.125.4.1506","article-title":"Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in\u00a0vitro","volume":"125","author":"Ritz","year":"1980","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.beha.2012.04.004_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.126.2.540","article-title":"Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody","volume":"126","author":"Pesando","year":"1981","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.beha.2012.04.004_bib21","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.004_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","article-title":"Monoclonal antibody-based therapies of leukemia and lymphoma","volume":"80","author":"Grossbard","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2012.04.004_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1053-4296(00)80045-4","article-title":"Clinical radioimmunotherapy","volume":"10","author":"Knox","year":"2000","journal-title":"Semin Radiat Oncol"},{"issue":"2 Suppl.","key":"10.1016\/j.beha.2012.04.004_bib24","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ijrobp.2006.04.059","article-title":"Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma","volume":"66","author":"Meredith","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6\u00a0Suppl. 12","key":"10.1016\/j.beha.2012.04.004_bib25","first-page":"62","article-title":"Principles of radioimmunotherapy for hematologists and oncologists","volume":"27","author":"Press","year":"2000","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2012.04.004_bib26","first-page":"2123","article-title":"Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells","volume":"56","author":"Press","year":"1996","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.beha.2012.04.004_bib27","first-page":"1230","article-title":"Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy","volume":"39","author":"Gates","year":"1998","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.beha.2012.04.004_bib28","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.beha.2012.04.004_bib29","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","article-title":"Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma","volume":"10","author":"Kaminski","year":"1992","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2012.04.004_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2012.04.004_bib31","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol"},{"issue":"Suppl. 326","key":"10.1016\/j.beha.2012.04.004_bib32","article-title":"Randomized controlled study of iodine-131 anti-B1 antibody vs. unlabeled-anti-B1 antibody in subjects with chemotherapy refractory low-grade non-Hodgkin\u2019s lymphoma [abstract]","volume":"39","author":"Knox","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.beha.2012.04.004_bib33","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.004_bib34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2012.04.004_bib35","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2012.04.004_bib36","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2012.04.004_bib37","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2012.04.004_bib38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2012.04.004_bib39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2012.04.004_bib40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMe048291","article-title":"Radioimmunotherapy\u2013hot new treatment for lymphoma","volume":"352","author":"Connors","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.beha.2012.04.004_bib41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V116.21.593.593","article-title":"90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. First results from an international phase II trial","volume":"116","author":"Scholz","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2012.04.004_bib42","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of southwest oncology group protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.004_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood.V118.21.98.98","article-title":"A phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs. CHOP chemotherapy plus iodine-131-tositumomab for the treatment of newly diagnosed follicular non-Hodgkin's lymphoma","volume":"118","author":"Press","year":"2011","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.beha.2012.04.004_bib44","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.beha.2012.04.004_bib45","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18S","key":"10.1016\/j.beha.2012.04.004_bib46","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1200\/jco.2006.24.18_suppl.7560","article-title":"Sequential radioimmunotherapy with tositumomab\/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Zelenetz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.004_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.V110.11.389.389","article-title":"Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: eastern cooperative oncology group study E1499","volume":"110","author":"Smith","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2012.04.004_bib48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","article-title":"Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab","volume":"112","author":"Gopal","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.004_bib49","unstructured":"Smith MR, Chen H, Gordon L, et\u00a0al. Phase II study of R-CHOP followed by 90Y-Ibritumomab tiuxetan in untreated mantle cell lymphoma (MCL): 5 year follow-up of Eastern Cooperative Oncology group E1499. In. Presented at the 11th international conference on malignant lymphoma. Lugano, Switzerland; 2011."},{"issue":"9","key":"10.1016\/j.beha.2012.04.004_bib50","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1987.5.9.1340","article-title":"Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation","volume":"5","author":"Appelbaum","year":"1987","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2012.04.004_bib51","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.1990.8.5.784","article-title":"Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse","volume":"8","author":"Freedman","year":"1990","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2012.04.004_bib52","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2012.04.004_bib53","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"issue":"8971","key":"10.1016\/j.beha.2012.04.004_bib54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas","volume":"346","author":"Press","year":"1995","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.beha.2012.04.004_bib55","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2012.04.004_bib56","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2012.04.004_bib57","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2012.04.004_bib58","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":"Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"27","author":"Winter","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261200031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261200031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T10:45:40Z","timestamp":1713955540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261200031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S152169261200031X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.04.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}